Or at least I hope that's the case. With the shift to focus on cancer and liver disease and its acquisition of Bridge Medicines' acute myeloid leukemia preclinical asset, the company is making all the right moves that can secure long-term success. Now we have to wait and see if it'll work.
There are no replies in this thread yet. Be the first to post a reply below: